Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15

Gastroenterology

Volumn 123, Issue 6, 2002, Pages 2041-2051

  Hillebrandt, Sonja ^a   Goos, Claudia ^a   Matern, Siegfried ^a   Lammert, Frank ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMOSOME 15; CHROMOSOME 2; CONTROLLED STUDY; GENE; GENE MAPPING; GENETIC ANALYSIS; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENOME; HEPATIC FIBROGENIC GENE 1; HISTOLOGY; INBRED STRAIN; LIVER FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; RECESSIVE INHERITANCE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 0036892365     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.37069     Document Type: Article

References (58)

1. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500-1511.
2. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247-2250.
3. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001;21:397-416.
4. Ramadori G, Armbrust T. Cytokines in the liver. Eur J Gastroenterol Hepatol 2001;13:777-784.
5. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001;21:351-372.
6. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
7. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, Jonsson JR. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000;31:828-833.
8. Friedman SL. The virtuosity of hepatic stellate cells. Gastroenterology 1999;117:1244-1246.
9. Gordon MA, Oppenheim E, Camp NJ, di Giovine FS, Duff GW, Gleeson D. Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor α promoter region. J Hepatol 1999;31:242-247.
10. Jones DE, Watt FE, Grove J, Newton JL, Daly AK, Gregory WL, Day CP, James OF, Bassendine MF. Tumour necrosis factor-α promoter polymorphisms in primary biliary cirrhosis. J Hepatol 1999;30:232-236.
11. Tanaka A, Quaranta S, Mattalia A, Coppel R, Rosina F, Manns MP, Gershwin ME. The tumor necrosis factor-α promoter correlates with progression of primary biliary cirrhosis. J Hepatol 1999;30:826-829.
12. Agarwal K, Jones DE, Daly AK, James OF, Vaidya B, Pearce S, Bassendine MF. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol 2000;32:538-541.
13. Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000;46:540-545.
14. Donaldson P, Agarwal K, Craggs A, Craig W, James O, Jones D. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: Associations with disease progression and disease susceptibility. Gut 2001;48:397-402.
15. Donaldson PT, Day CP. Predictive value of cytokine polymorphisms for liver disease. In: Gressner AM, Heinrich PC, Matern S, eds. Cytokines in Liver Injury and Repair. Dordrecht, the Netherlands: Kluwer Academic, 2002:253-265.
16. Gewaltig J, Mangasser-Stephan K, Gartung C, Biesterfeld S, Gressner AM. Association of polymorphisms of the transforming growth factor-β1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta 2002;316:83-94.
17. Paigen K. A miracle enough: The power of mice. Nat Med 1995;1:215-220.
18. Tsukamoto H, Matsuoka M, French SW. Experimental models of hepatic fibrosis: A review. Semin Liver Dis 1990;10:56-65.
19. Shi Z, Wakil AE, Rockey DC. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci U S A 1997;94:10663-10668.
20. Darvasi A. Experimental strategies for the genetic dissection of complex traits in animal models. Nat Genet 1998;18:19-24.
21. Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 1981;112:70-75.
22. Kellner R, Meyer HE, Lottspeich F. Amino acid analysis. In: Kellner R, Lottspeich F, Meyer HE, eds. Microcharacterization of Proteins. Weinheim, Germany: VCH, 1994:93-113.
23. Waldrop FS, Puchtler H. Light microscopic distinction of collagens in hepatic cirrhosis. Histochemistry 1982;74:487-491.
24. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409-1417.
25. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, Phillips MJ, Portmann BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
26. Ropers T, Kroll W, Becka M, Voelker M, Burchardt ER, Schuppan D, Gehrmann M. Enzyme immunoassay for the measurement of human tenascin-C on the Bayer Immuno 1 analyzer. Clin Biochem 2000;33:7-13.
27. Manly KF, Olson JM. Overview of QTL mapping software and introduction to Map Manager QT. Mamm Genome 1999;10:327-334.
28. Haley CS, Knott SA. A simple regression method for mapping quantitative trait loci in line crosses using flanking markers. Heredity 1992;69:315-324.
29. Lander ES, Botstein D. Mapping Mendelian factors underlying quantitative traits using RFLP linkage maps. Genetics 1989;121:185-199.
30. Jansen RC. Interval mapping of multiple quantitative trait loci. Genetics 1993;135:205-211.
31. Darvasi A, Soller M. Selective genotyping for determination of linkage between a marker locus and a quantitative trait. Theor Appl Genet 1992;85:353-359.
32. Dupuis J, Siegmund D. Statistical methods for mapping quantitative trait loci from a dense set of markers. Genetics 1999;151:373-386.
33. Grupe A, Germer S, Usuka J, Aud D, Belknap JK, Klein RF, Ahluwalia MK, Higuchi R, Peltz G. In silico mapping of complex disease-related traits in mice. Science 2001;292:1915-1918.
34. Chesler EJ, Rodriguez-Zas SL, Mogil JS. In silico mapping of mouse quantitative trait loci. Science 2001;294:2423a.
35. Lander E, Kruglyak L. Genetic dissection of complex traits: Guidelines for interpreting and reporting linkage results. Nat Genet 1995;11:241-247.
36. Maltais LJ, Blake JA, Eppig JT, Davisson MT. Rules and guidelines for mouse gene nomenclature: A condensed version. International Committee on Standardized Genetic Nomenclature for Mice. Genomics 1997;45:471-476.
37. Darvasi A, Weinreb A, Minke V, Weller JI, Soller M. Detecting marker-QTL linkage and estimating QTL gene effect and map location using a saturated genetic map. Genetics 1993;134:943-951.
38. Höhler T, Krüger A, Gerken G, Schneider PM, Meyer zum Büsschenfelde KH, Rittner C. Tumor necrosis factor αpromoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol 1998;54:173-177.
39. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon α. Hepatology 1999;30:526-530.
40. Yee LJ, Tang J, Herrera J, Kaslow RA, van Leeuwen DJ. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000;1:386-390.
41. Lora JM, Farlow DN, Weich NS, Gutiérrez-Ramos JC. A genomic view of hepatology: The example of liver fibrosis. In: Arias IM, Boyer JL, Chisari FV, Fausto N, Schachter D, Shafritz DA, eds. The Liver: Biology and Pathobiology. Philadelphia: Lippincott Williams & Wilkins, 2001:909-916.
42. Chiaramonte MG, Cheever AW, Malley JD, Donaldson DD, Wynn TA. Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology 2001;34:273-282.
43. Abitbol M, Puy H, Jouault H, Guenet JL, Deybach JC, Nordmann Y, Montagutelli X. Influence of the genetic background on the severity of the phenotype of the ferrochelatase deficiency (FECHM1PAS) mutation, a mouse model for human erythropoietic protoporphyria. In: Jackson IJ, Miller D, eds. 15th International Mouse Genome Conference. Final Program and Book of Abstracts, October 21-24, 2001, Edinburgh, Scotland. Edinburgh: Conference Ltd, 2001:58.
44. Jin DK, Vacher J, Feuerman MH. α-fetoprotein gene sequences mediating Afr2 regulation during liver regeneration. Proc Natl Acad Sci U S A 1998;95:8767-8772.
45. Weigel PH, Hascall VC, Tammi M. Hyaluronan synthases. J Biol Chem 1997;272:13997-14000.
46. Toole BP. Hyaluronan is not just a goo! J Clin Invest 2000;106:335-336.
47. Wolf D, Schumann J, Koerber K, Kiemer AK, Vollmar AM, Sass G, Papadopoulos T, Bang R, Klein SD, Brune B, Tiegs G. Low-molecular-weight hyaluronic acid induces nuclear factor-κB-dependent resistance against tumor necrosis factor α-mediated liver injury in mice. Hepatology 2001;34:535-547.
48. Li Y, Rahmanian M, Widstrom C, Lepperdinger G, Frost GI, Heldin P. Irradiation-induced expression of hyaluronan (HA) synthase 2 and hyaluronidase 2 genes in rat lung tissue accompanies active turnover of HA and induction of types I and III collagen gene expression. Am J Respir Cell Mol Biol 2000;23:411-418.
49. Plevris JN, Haydon GH, Simpson KJ, Dawkes R, Ludlum CA, Harrison DJ, Hayes PC. Serum hyaluronan - A non-invasive test for diagnosing liver cirrhosis. Eur J Gastroenterol Hepatol 2000;12:1121-1127.
50. Bartosiewicz MJ, Jenkins D, Penn S, Emery J, Buckpitt A. Unique gene expression patterns in liver and kidney associated with exposure to chemical toxicants. J Pharmacol Exp Ther 2001;297:895-905.
51. Bulera SJ, Eddy SM, Ferguson E, Jatkoe TA, Reindel JF, Bleavins MR, De La Iglesia FA. RNA expression in the early characterization of hepatotoxicants in Wistar rats by high-density DNA microarrays. Hepatology 2001;33:1239-1258.
52. Waring JF, Jolly RA, Ciurlionis R, Lum PY, Praestgaard JT, Morfitt DC, Buratto B, Roberts C, Schadt E, Ulrich RG. Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol Appl Pharmacol 2001;175:28-42.
53. Hopken UE, Lu B, Gerard NP, Gerard C. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 1996;383:86-89.
54. Henson R. Complementing asthma. Nat Immunol 2001;1:190-92.
55. Karp CL, Grupe A, Schadt E, Ewart SL, Keane-Moore M, Cuomo PJ, Kohl J, Wahl L, Kuperman D, Germer S, Aud D, Peltz G, Wills-Karp M. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat Immunol 2000;1:221-226.
56. Wahl SM, Frazier-Jessen M, Jin WW, Kopp JB, Sher A, Cheever AW. Cytokine regulation of schistosome-induced granuloma and fibrosis. Kidney Int 1997;51:1370-1375.
57. Vaillant B, Chiaramonte MG, Cheever AW, Soloway PD, Wynn TA. Regulation of hepatic fibrosis and extracellular matrix genes by the Th response: New insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol 2001;167:7017-7026.
58. Koleva M, Schlaf G, Landmann R, Götze O, Jungermann K, Schieferdecker HL. Induction of anaphylatoxin C5a receptors in rat hepatocytes by lipopolysaccharide in vivo: Mediation by interleukin-6 from Kupffer cells. Gastroenterology 2002;122:697-708.